Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (7563)	10/28/1998 10:25:00 AM
From: Bluegreen	Respond to of 17367

From that site you last posted Bob. "Its production peaks at 12 hours, and this is related to the excessive production of inflammatory cytokines have been produced, expression of LBP must be suppressed within 12 hours to inhibit this excessive reaction, and that will be the task of a future study." Now tell us why Xoma might be able to INCREASE LBP by exogenous methods and get away with it. Do they have some special type of LBP?<g> Seems like the individuals in this study are way behind the curve.......why would you suppress one of your main helpers in mopping up LPS? Can there possibly be a way to make LBP that doesn't affect the kick off of CD14? Could this special LBP be combined with rBPI21?<g>